From: Metastasis of breast cancer to bones alters the tumor immune microenvironment
Variable | N | % |
---|---|---|
Bone metastasis lesions | 63 | Â |
Primary tumor and matched bone metastasis | 31 | 49.21 |
Primary tumor histology | ||
 Ductal, non-special type | 51 | 80.95 |
 Ductal, micropapillary | 1 | 1.59 |
 Ductal, mucinous | 2 | 3.17 |
 Ductal and lobular | 2 | 3.17 |
 Uncertain | 7 | 11.11 |
Primary tumor grade | ||
 1 | 1 | 1.59 |
 2 | 15 | 23.81 |
 3 | 40 | 63.49 |
 Uncertain | 7 | 11.11 |
Primary tumor phenotypes | ||
 Luminal A | 11 | 17.46 |
 Luminal B | 29 | 46.03 |
 HER2 amplification | 15 | 23.81 |
 Triple-negative | 4 | 6.35 |
 Uncertain | 4 | 6.35 |
Primary tumor size | ||
  < 2 cm | 11 | 17.46 |
 2–5 cm | 24 | 38.10 |
  > 5 cm | 2 | 3.17 |
 Uncertain | 26 | 41.27 |
Nodes status | ||
 Negative | 10 | 15.87 |
 1–3 nodes | 20 | 31.75 |
 4–9 nodes | 4 | 6.35 |
  > 10 | 13 | 20.63 |
 Uncertain | 16 | 25.40 |
Surgery | ||
 Mastectomy | 44 | 69.84 |
 Breast conserving surgery | 5 | 7.94 |
 None | 5 | 7.94 |
 Uncertain | 9 | 14.29 |
Chemotherapy | ||
 Adjuvant | 54 | 85.71 |
 Neoadjuvant | 1 | 1.59 |
 None | 8 | 12.70 |
Radiotherapy | ||
 Adjuvant | 26 | 41.27 |
 None | 37 | 58.73 |
 Trastuzumab/pertuzumab application in HER2-positive patients | 7/15 |  |
Endocrine therapy | ||
 Yes | 40 | 63.49 |
 No | 23 | 36.51 |
 Bone metastasis at first diagnosis | 5 | 7.94 |
Bone metastasis sites | ||
 Ilium | 5 | 7.94 |
 Sternum | 7 | 11.11 |
 Rib | 1 | 1.59 |
 Vertebra | 43 | 68.25 |
 Femur | 3 | 4.76 |
 Humerus | 1 | 1.59 |
 Skull | 1 | 1.59 |
Treatment after bone metastasis | ||
 Radiotherapy | 8 | 12.70 |
 Chemotherapy | 27 | 42.86 |
 Endocrine therapy | 42 | 66.67 |
 Trastuzumab/pertuzumab | 4 | 6.35 |
 Alive at last follow-up | 43 | 68.25 |